Targeting E-Selectin With Uproleselan Confers Potential Efficacy and Safety Benefits in AML
November 3rd 2022Uproleselan, an agent that disrupts the interaction between leukemia cells and their protective E-selectin microenvironment, is a promising novel AML therapy that may increase the efficacy and durability of other AML treatments.
E-selectin Inhibitor Uproleselan May Bolster SOC Efficacy in AML
October 20th 2022Richard M. Stone, MD, highlights how uproleselan disrupts E-selectin in the AML tumor microenvironment, the variety of AML regimens that uproleselan may amplify in efficacy, including chemotherapies and venetoclax combinations, and the need for further research to determine whether minimal residual disease negativity rates will improve patient prognoses.
Uproleselan Plus Chemotherapy Could Provide MRD Benefit in Relapsed/Refractory AML
October 17th 2022Although the exact role of minimal residual disease in patients with acute myeloid leukemia requires further definition, MRD status could help provide a clearer pathway for treatment decisions in this patient population.
E-Selectin Upregulation and Chemo Combinations Among Recent Developments in AML
September 29th 2022E-selectin has emerged as a viable target in acute myeloid leukemia, and agents like uproleselan have the potential the increase AML cells’ sensitivity to chemotherapies such as cladribine plus low-dose cytarabine.